XML 32 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Segments of Business and Geographic Areas
 6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

SALES BY SEGMENT OF BUSINESS
 
 
Fiscal Second Quarter Ended
 
Fiscal Six Months Ended
(Dollars in Millions)
 
June 30,
2019
 
July 1,
2018
 
Percent
Change
 
June 30,
2019
 
July 1,
2018
 
Percent Change
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
$
99

 
89

 
11.5
 %
 
$
186

 
186

 
(0.2
)%
     International
 
344

 
367

 
(6.3
)
 
651

 
727

 
(10.5
)
     Worldwide
 
443

 
456

 
(2.8
)
 
837

 
913

 
(8.4
)
Beauty
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
663

 
637

 
4.1

 
1,251

 
1,248

 
0.3

     International
 
539

 
472

 
14.1

 
1,041

 
945

 
10.1

     Worldwide
 
1,202

 
1,109

 
8.4

 
2,292

 
2,193

 
4.5

Oral Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
155

 
157

 
(1.6
)
 
306

 
314

 
(2.5
)
     International
 
234

 
236

 
(0.7
)
 
450

 
458

 
(1.7
)
     Worldwide
 
389

 
393

 
(1.1
)
 
756

 
772

 
(2.0
)
OTC
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
484

 
454

 
6.6

 
991

 
919

 
7.8

     International
 
580

 
612

 
(5.1
)
 
1,160

 
1,219

 
(4.9
)
     Worldwide
 
1,064

 
1,066

 
(0.1
)
 
2,151

 
2,138

 
0.6

Women's Health
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3

 
4

 
(10.3
)
 
6

 
7

 
(3.7
)
     International
 
250

 
276

 
(9.5
)
 
472

 
516

 
(8.6
)
     Worldwide
 
253

 
280

 
(9.5
)
 
478

 
523

 
(8.5
)
Wound Care/Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
132

 
135

 
(1.9
)
 
234

 
238

 
(1.5
)
     International
 
61

 
65

 
(6.4
)
 
114

 
125

 
(8.9
)
     Worldwide
 
193

 
200

 
(3.4
)
 
348

 
363

 
(4.0
)
TOTAL CONSUMER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,537

 
1,476

 
4.1

 
2,975

 
2,912

 
2.2

     International
 
2,007

 
2,028

 
(1.0
)
 
3,887

 
3,990

 
(2.6
)
     Worldwide
 
3,544

 
3,504

 
1.2

 
6,862

 
6,902

 
(0.6
)
 
 
 
 
 
 
 
 
 
 
 
 
 

PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
2,379

 
2,317

 
2.7

 
4,542

 
4,317

 
5.2

     International
 
1,087

 
1,021

 
6.3

 
2,175

 
2,063

 
5.4

     Worldwide
 
3,466

 
3,338

 
3.8

 
6,717

 
6,380

 
5.3

     REMICADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
801

 
918

 
(12.7
)
 
1,575

 
1,834

 
(14.1
)
     U.S. Exports
 
62

 
104

 
(40.3
)
 
138

 
246

 
(43.9
)
     International
 
244

 
298

 
(18.5
)
 
496

 
629

 
(21.2
)
     Worldwide
 
1,107

 
1,320

 
(16.2
)
 
2,209

 
2,709

 
(18.5
)
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
281

 
274

 
2.7

 
544

 
498

 
9.1

     International
 
282

 
274

 
2.7

 
543

 
568

 
(4.4
)
     Worldwide
 
563

 
548

 
2.7

 
1,087

 
1,066

 
1.9

     STELARA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,058

 
919

 
15.2

 
1,940

 
1,571

 
23.5

     International
 
499

 
422

 
18.1

 
1,022

 
831

 
23.0

     Worldwide
 
1,558

 
1,341

 
16.1

 
2,963

 
2,402

 
23.3

     TREMFYA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
176

 
102

 
72.3
 
344

 
168

 
*
     International
 
59

 
24

 
*
 
108

 
30

 
*
     Worldwide
 
235

 
126

 
86.5
 
452

 
198

 
*
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—
 
—

 
—

 
—
     International
 
3

 
3

 
27.7
 
6

 
5

 
23.6
     Worldwide
 
3

 
3

 
27.7
 
6

 
5

 
23.6
 
 
 
 
 
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
387

 
328

 
17.8

 
744

 
661

 
12.5

     International
 
475

 
521

 
(8.7
)
 
964

 
1,018

 
(5.3
)
     Worldwide
 
862

 
849

 
1.5

 
1,708

 
1,679

 
1.7

     EDURANT® / rilpivirine
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
12

 
15

 
(15.8
)
 
24

 
29

 
(17.3
)
     International
 
198

 
196

 
0.5

 
397

 
392

 
1.4

     Worldwide
 
210

 
211

 
(0.6
)
 
421

 
421

 
0.1

     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
344

 
277

 
24.2

 
659

 
550

 
19.9

     International
 
191

 
215

 
(11.1
)
 
399

 
420

 
(5.0
)
     Worldwide
 
535

 
492

 
8.7

 
1,058

 
970

 
9.1

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
31

 
36

 
(16.6
)
 
61

 
82

 
(26.0
)
     International
 
86

 
110

 
(20.8
)
 
168

 
206

 
(18.6
)
     Worldwide
 
117

 
146

 
(19.7
)
 
229

 
288

 
(20.7
)
 
 
 
 
 
 
 
 
 
 
 
 
 

Neuroscience
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
664

 
639

 
3.8

 
1,387

 
1,263

 
9.8

     International
 
875

 
889

 
(1.6
)
 
1,780

 
1,824

 
(2.4
)
     Worldwide
 
1,538

 
1,528

 
0.6

 
3,167

 
3,087

 
2.6

     CONCERTA® / methylphenidate
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
15

 
68

 
(78.6
)
 
112

 
134

 
(16.4
)
     International
 
123

 
115

 
6.2

 
239

 
222

 
7.3

     Worldwide
 
137

 
183

 
(25.2
)
 
351

 
356

 
(1.6
)
     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
506

 
438

 
15.6

 
989

 
838

 
18.1

     International
 
312

 
282

 
10.4

 
619

 
578

 
7.0

     Worldwide
 
818

 
720

 
13.6

 
1,608

 
1,416

 
13.6

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
81

 
80

 
0.8

 
158

 
162

 
(3.0
)
     International
 
101

 
108

 
(6.5
)
 
203

 
222

 
(8.4
)
     Worldwide
 
182

 
188

 
(3.4
)
 
361

 
384

 
(6.2
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
62

 
53

 
16.1

 
128

 
129

 
(0.4
)
     International
 
340

 
384

 
(11.5
)
 
719

 
802

 
(10.3
)
     Worldwide
 
401

 
437

 
(8.1
)
 
847

 
931

 
(8.9
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,013

 
1,085

 
(6.6
)
 
1,975

 
2,018

 
(2.1
)
     International
 
1,684

 
1,371

 
22.8

 
3,240

 
2,749

 
17.9

     Worldwide
 
2,697

 
2,456

 
9.8

 
5,215

 
4,767

 
9.4

     DARZALEX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
369

 
298

 
24.4

 
721

 
562

 
28.5

     International
 
405

 
213

 
89.5

 
682

 
381

 
78.7

     Worldwide
 
774

 
511

 
51.6

 
1,403

 
943

 
48.8

     IMBRUVICA®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
367

 
250

 
47.0

 
716

 
477

 
50.2

     International
 
463

 
370

 
25.3

 
898

 
730

 
23.1

     Worldwide
 
831

 
620

 
34.1

 
1,615

 
1,207

 
33.8

     VELCADE®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—
 
—

 
—

 
—
     International
 
224

 
280

 
(20.1
)
 
487

 
593

 
(17.9
)
     Worldwide
 
224

 
280

 
(20.1
)
 
487

 
593

 
(17.9
)
     ZYTIGA® / abiraterone acetate
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
198

 
486

 
(59.4
)
 
383

 
893

 
(57.1
)
     International
 
500

 
423

 
18.0

 
994

 
861

 
15.4

     Worldwide
 
698

 
909

 
(23.3
)
 
1,377

 
1,754

 
(21.5
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
78

 
51

 
50.5
 
154

 
86

 
77.7

     International
 
92

 
85

 
8.8

 
179

 
184

 
(2.5
)
     Worldwide
 
170

 
136

 
24.7

 
333

 
270

 
23.2

 
 
 
 
 
 
 
 
 
 
 
 
 

Pulmonary Hypertension
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
439

 
429

 
2.2
 
869

 
790

 
10.0

     International
 
251

 
236

 
6.7
 
477

 
460

 
3.7

     Worldwide
 
690

 
665

 
3.8
 
1,346

 
1,250

 
7.7

     OPSUMIT®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
203

 
180

 
12.8
 
375

 
329

 
14.2

     International
 
146

 
131

 
11.5
 
279

 
253

 
10.3

     Worldwide
 
348

 
311

 
12.3
 
654

 
582

 
12.5

     TRACLEER®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
41

 
71

 
(41.8)
 
102

 
139

 
(26.3
)
     International
 
62

 
72

 
(14.5)
 
118

 
144

 
(18.7
)
     Worldwide
 
103

 
143

 
(28.0)
 
220

 
283

 
(22.4
)
     UPTRAVI®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
175

 
155

 
13.4
 
351

 
279

 
25.9

     International
 
28

 
16

 
62.5
 
50

 
32

 
53.1

     Worldwide
 
203

 
171

 
18.2
 
401

 
311

 
28.7

     OTHER 
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
20

 
23

 
(18.2)
 
41

 
43

 
(8.4
)
     International
 
16

 
17

 
3.7
 
31

 
31

 
4.1

     Worldwide
 
37

 
40

 
(9.6)
 
72

 
74

 
(3.4
)
 
 
 
 
 
 
 
 
 
 
 
 
 
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
902

 
1,101

 
(18.1
)
 
1,849

 
2,204

 
(16.1
)
     International
 
373

 
417

 
(10.5
)
 
771

 
831

 
(7.2
)
     Worldwide
 
1,275

 
1,518

 
(16.0
)
 
2,620

 
3,035

 
(13.7
)
     XARELTO®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
549

 
679

 
(19.2
)
 
1,091

 
1,257

 
(13.2
)
     International
 
—

 
—

 
—
 
—

 
—

 
—
     Worldwide
 
549

 
679

 
(19.2
)
 
1,091

 
1,257

 
(13.2
)
     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
132

 
169

 
(21.2
)
 
286

 
373

 
(23.2
)
     International
 
43

 
46

 
(6.0
)
 
92

 
90

 
2.6

     Worldwide
 
177

 
215

 
(17.9
)
 
379

 
463

 
(18.2
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
113

 
156

 
(27.5
)
 
261

 
345

 
(24.3
)
     International
 
70

 
80

 
(13.4
)
 
148

 
167

 
(11.7
)
     Worldwide
 
183

 
236

 
(22.7
)
 
409

 
512

 
(20.2
)
     OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
107

 
97

 
9.3

 
211

 
229

 
(8.2
)
     International
 
260

 
291

 
(10.5
)
 
531

 
574

 
(7.5
)
     Worldwide
 
368

 
388

 
(5.5
)
 
742

 
803

 
(7.7
)
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
5,783

 
5,899

 
(2.0
)
 
11,365

 
11,253

 
1.0

     International
 
4,746

 
4,455

 
6.5

 
9,408

 
8,945

 
5.2

     Worldwide
 
10,529

 
10,354

 
1.7

 
20,773

 
20,198

 
2.8

 
 
 
 
 
 
 
 
 
 
 
 
 

MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
—

 
129

 
*
 
—

 
246

 
*

     International
 
—

 
226

 
*
 
—

 
448

 
*

     Worldwide
 
—

 
355

 
*
 
—

 
694

 
*

Interventional Solutions
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
366

 
323

 
13.7

 
709

 
627

 
13.2

     International
 
385

 
344

 
11.6

 
774

 
680

 
13.7

     Worldwide
 
750

 
667

 
12.6

 
1,482

 
1,307

 
13.4

Orthopaedics
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
1,331

 
1,332

 
(0.1
)
 
2,649

 
2,639

 
0.4

     International
 
894

 
930

 
(3.8
)
 
1,779

 
1,873

 
(5.0
)
     Worldwide
 
2,224

 
2,262

 
(1.6
)
 
4,428

 
4,512

 
(1.9
)
     HIPS
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
216

 
211

 
2.1

 
429

 
420

 
2.1

     International
 
147

 
149

 
(0.7
)
 
295

 
303

 
(2.3
)
     Worldwide
 
364

 
360

 
0.9

 
725

 
723

 
0.3

     KNEES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
218

 
229

 
(4.8
)
 
441

 
457

 
(3.5
)
     International
 
153

 
153

 
0.4

 
299

 
312

 
(4.0
)
     Worldwide
 
372

 
382

 
(2.8
)
 
741

 
769

 
(3.7
)
     TRAUMA
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
407

 
394

 
3.3

 
824

 
801

 
2.9

     International
 
265

 
281

 
(5.9
)
 
533

 
570

 
(6.5
)
     Worldwide
 
672

 
675

 
(0.6
)
 
1,357

 
1,371

 
(1.0
)
     SPINE & OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
490

 
498

 
(1.5
)
 
955

 
961

 
(0.6
)
     International
 
328

 
347

 
(5.3
)
 
651

 
688

 
(5.4
)
     Worldwide
 
818

 
845

 
(3.1
)
 
1,606

 
1,649

 
(2.6
)
Surgery
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
926

 
1,022

 
(9.5
)
 
1,927

 
2,015

 
(4.4
)
     International
 
1,427

 
1,493

 
(4.4
)
 
2,821

 
2,923

 
(3.5
)
     Worldwide
 
2,353

 
2,515

 
(6.5
)
 
4,748

 
4,938

 
(3.9
)
     ADVANCED
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
396

 
402

 
(1.7
)
 
800

 
795

 
0.6

     International
 
633

 
603

 
5.0

 
1,209

 
1,176

 
2.8

     Worldwide
 
1,029

 
1,005

 
2.3

 
2,009

 
1,971

 
1.9

     GENERAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
443

 
436

 
1.6

 
868

 
859

 
1.0

     International
 
674

 
733

 
(7.9
)
 
1,339

 
1,437

 
(6.8
)
     Worldwide
 
1,119

 
1,169

 
(4.3
)
 
2,208

 
2,296

 
(3.9
)
     SPECIALTY
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
87

 
184

 
(53.1
)
 
259

 
361

 
(28.3
)
     International
 
120

 
157

 
(23.7
)
 
273

 
310

 
(12.1
)
     Worldwide
 
206

 
341

 
(39.6
)
 
531

 
671

 
(20.8
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Vision
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
461

 
459

 
0.4

 
907

 
899

 
1.0

     International
 
701

 
714

 
(2.0
)
 
1,383

 
1,389

 
(0.5
)
     Worldwide
 
1,161

 
1,173

 
(1.0
)
 
2,290

 
2,288

 
0.1

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
333

 
320

 
3.9

 
654

 
629

 
4.0

     International
 
509

 
524

 
(2.9
)
 
1,011

 
1,022

 
(1.0
)
     Worldwide
 
842

 
844

 
(0.3
)
 
1,666

 
1,651

 
0.9

     SURGICAL
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
128

 
139

 
(7.7
)
 
253

 
270

 
(6.1
)
     International
 
191

 
190

 
0.7

 
371

 
367

 
1.0

     Worldwide
 
319

 
329

 
(2.8
)
 
624

 
637

 
(2.0
)
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
3,083

 
3,265

 
(5.6
)
 
6,192

 
6,426

 
(3.6
)
     International
 
3,406

 
3,707

 
(8.1
)
 
6,756

 
7,313

 
(7.6
)
     Worldwide
 
6,489

 
6,972

 
(6.9
)
 
12,948

 
13,739

 
(5.7
)
 
 
 
 
 
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
 
 
 
 
 
     U.S.
 
10,403

 
10,640

 
(2.2
)
 
20,532

 
20,591

 
(0.3
)
     International
 
10,159

 
10,190

 
(0.3
)
 
20,051

 
20,248

 
(1.0
)
     Worldwide
 
$
20,562

 
20,830

 
(1.3
)%
 
$
40,583

 
40,839

 
(0.6
)%

*Percentage greater than 100% or not meaningful

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 
 
Fiscal Second Quarter Ended
 
Fiscal Six Months Ended
(Dollars in Millions)
 
June 30,
2019
 
July 1,
2018
 
Percent
Change
 
June 30,
2019
 
July 1,
2018
 
Percent Change
Consumer (1)
 
$
406

 
829

 
(51.0
)%
 
$
1,147

 
1,377

 
(16.7
)%
Pharmaceutical(2)
 
3,677

 
3,651

 
0.7

 
6,008

 
7,317

 
(17.9
)
Medical Devices(3)
 
3,189

 
796

 
*

 
4,686

 
2,375

 
97.3

Segment earnings before provision for taxes
 
7,272

 
5,276

 
37.8

 
11,841

 
11,069

 
7.0

Less: Expense not allocated to segments (4)
 
231

 
303

 
 

 
378

 
615

 
 

Worldwide income before tax
 
$
7,041

 
4,973

 
41.6
 %
 
$
11,463

 
10,454

 
9.7
 %

*Percentage greater than 100%

(1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) in the fiscal six months of 2019. Includes a gain of $0.3 billion from the divestiture of NIZORAL® in the fiscal second quarter and six months of 2018. Includes amortization expense of $0.1 billion and $0.1 billion in the fiscal second quarters and $0.2 billion and $0.1 billion in the fiscal six months of 2019 and 2018, respectively. Includes litigation expense of $0.2 billion in the fiscal second quarter and fiscal six months of 2019.
 
(2) Includes an unrealized gain on securities of $0.2 billion and Actelion acquisition related costs of $0.1 billion in the fiscal second quarter of 2019. Includes an unrealized gain on securities of $0.3 billion, an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, litigation expense of $0.4 billion, and Actelion acquisition related costs of $0.1 billion in the fiscal six months of 2019. Includes Actelion acquisition related costs of $0.1 billion and $0.2 billion in the fiscal second quarter and fiscal six months of 2018, respectively and a gain of $0.1 billion from the divestiture of PANCREASE® in the fiscal second quarter and six months of 2018. Includes amortization expense of $0.8 billion and $0.8 billion in the fiscal second quarters and $1.6 billion and $1.5 billion in the fiscal six months of 2019 and 2018, respectively.
(3) Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal second quarter and six months of 2019. Includes a restructuring related charge of $0.1 billion and $0.1 billion in the fiscal second quarters of 2019 and 2018, respectively and $0.1 billion and $0.2 billion in the fiscal six months of 2019 and 2018, respectively. Includes litigation expense of $0.2 billion and $0.7 billion in the fiscal second quarters of 2019 and 2018, respectively and $0.3 billion and $0.7 billion in the fiscal six months of 2019 and 2018, respectively. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal second quarters of 2019 and 2018, respectively and $0.5 billion and $0.5 billion in the fiscal six months of 2019 and 2018, respectively.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

SALES BY GEOGRAPHIC AREA
 
 
Fiscal Second Quarter Ended
 
Fiscal Six Months Ended
(Dollars in Millions)
 
June 30, 2019
 
July 1, 2018
 
Percent
Change
 
June 30, 2019
 
July 1, 2018
 
Percent Change
United States
 
$
10,403

 
10,640

 
(2.2
)%
 
$
20,532

 
20,591

 
(0.3
)%
Europe
 
4,733

 
4,810

 
(1.6
)
 
9,342

 
9,607

 
(2.8
)
Western Hemisphere, excluding U.S.
 
1,455

 
1,540

 
(5.5
)
 
2,958

 
3,107

 
(4.8
)
Asia-Pacific, Africa
 
3,971

 
3,840

 
3.4

 
7,751

 
7,534

 
2.9

Total
 
$
20,562

 
20,830

 
(1.3
)%
 
$
40,583

 
40,839

 
(0.6
)%